Research shows that identifying the underlying barriers is challenging for patients and practitioners. The goal of this project is to use a questionnaire developed by this research team to identify an individual’s barriers to medication adherence. Principal Investigator. Team led by Dr Debi Bhattacharya. Full validation of IMAB-Q has been published

Description: IMAB-Q is a programme of work to develop a theory and evidence-based tool to guide practitioners and patients to diagnose an individuals main barriers to adherence. The IMAB-Q 30 and 10 item versions are available here: https://www.uea.ac.uk/groups-and-centres/patient-care-group/imab-q.

The IMAB-Q is a valid and reliable tool for identifying patients not adhering to their prescribed medicines and their main barriers to adherence that require targeting. Each IMAB-Q item is linked to a TDF domain which in turn is linked to relevant behaviour change techniques.

Nov 17, 2023 · Purpose: To validate the Identification of Medication Adherence Barriers Questionnaire (IMAB-Q) as a tool to guide practitioners to identify patients who require support to take their medicines as prescribed, their key barriers to adherence and select relevant behaviour change techniques.

Is IMAB-Q valid, reliable and suitable for identifying medication adherence barriers in routine community pharmacy practice? Aims and objectives To investigate the following: 1) Psychometric properties of IMAB-Q: construct and criterion validity, …

The IMAB-Q is a robustly developed and theory guided tool with the potential to influence future adherence intervention design. However, the validity and reliability of the questionnaire need to be established.

Barriers to adherence were identified using the Identification of Medication Adherence Barriers Questionnaire 30 (IMAB-Q 30). Associations between adherence and patient demographics and disease-specific characteristics were explored.

... analysis showed a significant relationship between barriers to medication adherence and adherence to treatment in patients in primary health centers in Surabaya (r = 0.304; p < 0.001), while...

Nov 17, 2023 · The IMAB-Q is a valid and reliable tool for identifying patients not adhering to their prescribed medicines and their main barriers to adherence that require targeting. Each IMAB-Q item is linked to a TDF domain which in turn is linked to relevant behaviour change techniques.

I-Mab (NASDAQ: IMAB), a US-based biotechnology firm focused on innovative cancer immunotherapies, announced on Wednesday that it will present optimised dose estimation data for its bispecific antibody givastomig (TJ033721/ABL111) during a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) conference on 9 November 2024.